- Drug discovery firm Compugen (NASDAQ:CGEN) will unveil a new immune checkpoint target candidate, CGEN-15029, today at its Analyst and Investor Day in New York City. The affair will start at 9:00 am ET.
- Initial validation studies show that CGEN-15029 expression in T cells inhibits their activation by melanoma cells which is consistent with its tumor suppressive role.
- The company will also present its new computational infrastructure called LINKS, an in silico platform designed for the comprehensive and comparative assessment of drug targets.